High-throughput screening: update on practices and success.
High-throughput screening (HTS) has become an important part of drug discovery at most pharmaceutical and many biotechnology companies worldwide, and use of HTS technologies is expanding into new areas. Target validation, assay development, secondary screening, ADME/Tox, and lead optimization are among the areas in which there is an increasing use of HTS technologies. It is becoming fully integrated within drug discovery, both upstream and downstream, which includes increasing use of cell-based assays and high-content screening (HCS) technologies to achieve more physiologically relevant results and to find higher quality leads. In addition, HTS laboratories are continually evaluating new technologies as they struggle to increase their success rate for finding drug candidates. The material in this article is based on a 900-page HTS industry report involving 54 HTS directors representing 58 HTS laboratories and 34 suppliers.
Fox
Sandra
S
HighTech Business Decisions, Moraga, California 94556, USA. sfox@hightechdecisions.com
Farr-Jones
Shauna
S
Sopchak
Lynne
L
Boggs
Amy
A
Nicely
Helen Wang
HW
Khoury
Richard
R
Biros
Michael
M
D002477:Cells / Q000187:drug effects / Q000378:metabolism; D004353:Drug Evaluation, Preclinical / Q000379:methods* / Q000639:trends*; D006801:Humans; D004364:Pharmaceutical Preparations / Q000032:analysis
D004364:Pharmaceutical Preparations